New Jersey joins wave of states proposing new rules for drug marketing and HCP interactions

Drug manufacturers are once again facing new state limits on marketing and interactions with healthcare providers. Manufacturers should review the new laws and regulations carefully, consider how they might engage with the agencies interpreting the new limits, and begin preparing their own compliance efforts.

Read More: New Jersey Joins Wave of States Proposing New Rules for Drug Marketing and HCP Interactions

Download PDF Back To Listing